Johnson & Johnson (NYSE:JNJ) Shares Sold by KFG Wealth Management LLC

KFG Wealth Management LLC lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 9.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,285 shares of the company’s stock after selling 526 shares during the period. KFG Wealth Management LLC’s holdings in Johnson & Johnson were worth $764,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of JNJ. Dark Forest Capital Management LP purchased a new position in Johnson & Johnson in the 2nd quarter valued at about $223,000. Invst LLC raised its position in shares of Johnson & Johnson by 11.7% in the second quarter. Invst LLC now owns 2,083 shares of the company’s stock valued at $305,000 after buying an additional 218 shares during the last quarter. Quarry LP purchased a new position in shares of Johnson & Johnson during the second quarter valued at approximately $49,000. Gateway Wealth Partners LLC boosted its position in Johnson & Johnson by 12.6% during the second quarter. Gateway Wealth Partners LLC now owns 2,412 shares of the company’s stock worth $352,000 after acquiring an additional 270 shares during the last quarter. Finally, Truist Financial Corp raised its holdings in Johnson & Johnson by 4.9% in the 2nd quarter. Truist Financial Corp now owns 2,122,856 shares of the company’s stock valued at $310,277,000 after acquiring an additional 98,903 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 1.5 %

JNJ opened at $150.63 on Wednesday. The firm’s 50 day moving average is $147.81 and its 200-day moving average is $156.12. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $362.65 billion, a P/E ratio of 22.65, a P/E/G ratio of 2.45 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same period in the prior year, the company posted $2.29 EPS. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. Analysts expect that Johnson & Johnson will post 10.56 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.29%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Insider Activity

In related news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on JNJ. Citigroup dropped their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 16th. Raymond James lowered their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Morgan Stanley cut their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $170.44.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.